The Motley Fool Discussion Boards

Previous Page

Stocks I / Immunomedics, Inc.


Subject:  More news Date:  3/3/2000  8:25 AM
Author:  dboyer22 Number:  35 of 89

From MSN:

Immunomedics Reports Successful Delivery of Cancer Drugs by Bispecific Fusion Proteins

March 3, 2000 07:30 AM

PRINCETON, N.J., March 3 /PRNewswire/ -- Immunomedics, Inc. IMMU announced today that results with its proprietary bispecific fusion protein method for selective targeting of cancer drugs were presented at the International Conference on Advances in Cancer Immunotherapy.
According to the Company's Chairman and CEO, Dr. David M. Goldenberg, "Our scientists have reported the successful selective delivery of Doxorubicin, a prominent cancer drug, to human colonic cancers growing in mice. This was achieved by using a bispecific fusion protein that binds to the cancer and also binds the drug carrier when it is given in a second step."

"Immunomedics' chemists have constructed carrier molecules bearing Doxorubicin which are stable and attach to the bispecific fusion proteins targeted to the cancers. This results in relatively high uptake of the drug at the tumor site with ratios approaching 100:1 compared to normal tissues," Dr. Goldenberg explained. "We are excited that this is as close to the original hope for "silver bullets" as has been achieved in this field to date, and that we may be able to eventually apply this to many other promising cancer drugs," he added.

Dr. Goldenberg cautioned, "it is a long step from successful animal studies to clinical efficacy." "We are progressing rapidly from preclinical investigations to eventual clinical testing," he also remarked.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. The Company's first product, CEA-Scan(R) for the detection of colorectal cancer, is being marketed in the United States and Europe (approved in Canada). The Company's second diagnostic imaging product, LeukoScan(R), is being marketed in Europe for the diagnosis of osteomyelitis (bone infection). Immunomedics also has several other diagnostic imaging products and three therapeutic products in clinical trials.

This release, in addition to historical information, contains forward- looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company's Quarterly Report on Form 10-Q for the year ended December 31, 1999.

Company Contact: Cynthia L. Sullivan, Executive Vice President, 973-605-8200, extension 109. Visit the web site at

SOURCE Immunomedics, Inc.


Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us